The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 10, pp. 1502-1505. DOI 10.1345/aph.1C474
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L

OBJETIVO: Revisar la información disponible sobre la combinación aspirina/warfarina versus aspirina sola para la prevención secundaria luego de un infarto al miocardio.

FUENTES DE INFORMACION: Se identificó la literatura utilizando MEDLINE (1966–septiembre 2002). Los términos de la búsqueda incluyeron aspirina, warfarina, prevención secundaria, e infarto al miocardio.

SINTESIS: A pesar del uso de dosis bajas de aspirina post-infarto al miocardio, el riesgo de muerte subsiguiente y de eventos isquémicos continúa alto lo que hace imperativo que se desarrollen estrategias para prevención secundaria. Se evaluaron estudios relevantes, grandes y a largo plazo enfocando en terapia dual de aspirina/warfarina versus aspirina solamente en pacientes post-infarto al miocardio.

CONCLUSIONES: Aspirina 75–325 mg debe continuar como la terapia de primera línea en prevención post-infarto al miocardio. La combinación de aspirina 75–81 mg con warfarina (INR 2–2.5) podría proveer beneficio adicional pero sólo debe ser considerada en pacientes con un alto riesgo de eventos tromboembólicos.




This article has been cited by other articles:


Home page
 CirculationHome page
U. Stenestrand, J. Lindback, L. Wallentin, and for the RIKS-HIA Registry
Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term Outcome: A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)
Circulation, November 22, 2005; 112(21): 3225 - 3231.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeddy, A. S
Right arrow Articles by Gleason, B. L

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.